{
  "input": {
    "mode": "report_and_evolve",
    "query": {
      "entity": "Gastrointestinal epithelial barrier disorders",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_mesalamine",
          "name": "Mesalamine"
        },
        "mechanism_outline": "",
        "priority": 1.0
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_infliximab",
          "name": "Infliximab"
        },
        "mechanism_outline": "",
        "priority": 0.95
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_azathioprine",
          "name": "Azathioprine"
        },
        "mechanism_outline": "",
        "priority": 0.9
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_budesonide",
          "name": "Budesonide"
        },
        "mechanism_outline": "",
        "priority": 0.85
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_ustekinumab",
          "name": "Ustekinumab"
        },
        "mechanism_outline": "",
        "priority": 0.8
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_methotrexate",
          "name": "Methotrexate"
        },
        "mechanism_outline": "",
        "priority": 0.75
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_certolizumab_pegol",
          "name": "Certolizumab pegol"
        },
        "mechanism_outline": "",
        "priority": 0.7
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_golimumab",
          "name": "Golimumab"
        },
        "mechanism_outline": "",
        "priority": 0.6499999999999999
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_vedolizumab",
          "name": "Vedolizumab"
        },
        "mechanism_outline": "",
        "priority": 0.6
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_linaclotide",
          "name": "Linaclotide"
        },
        "mechanism_outline": "",
        "priority": 0.55
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_rifaximin",
          "name": "Rifaximin"
        },
        "mechanism_outline": "",
        "priority": 0.5
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_eluxadoline",
          "name": "Eluxadoline"
        },
        "mechanism_outline": "",
        "priority": 0.44999999999999996
      }
    ],
    "scores": [
      {
        "hypothesis_id": "H1",
        "score": 0.45,
        "components": {
          "mechanism_fit": 0.6,
          "class_prior": 0.5,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.3,
          "graph_bonus": 0.2,
          "conflict_penalty": 0.3
        },
        "graph_signals": {
          "support_weight": 2.55,
          "contradiction_weight": 1.55,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Mesalamine",
              "pro": [
                "drug_mesalamine"
              ],
              "con": [
                "n_adv_mesalamine"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Mesalamine抑制TNF-alpha，支持炎症反应通路的关键机制。"
          ],
          "safety_risk": [
            "Skeptic指出可能的副作用显著影响治疗效果。"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Mesalamine的副作用数据及其临床影响尚需更多证据。"
        ]
      },
      {
        "hypothesis_id": "H2",
        "score": 0.52,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.4,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.35
        },
        "graph_signals": {
          "support_weight": 2.2,
          "contradiction_weight": 1.55,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Infliximab",
              "pro": [
                "drug_infliximab"
              ],
              "con": [
                "n_adv_infliximab"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Infliximab直接抑制TNF-alpha，针对炎症反应。"
          ],
          "safety_risk": [
            "安全性风险可能对预期疗效造成影响。"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Infliximab对长期疗效的副作用需要进一步研究。"
        ]
      },
      {
        "hypothesis_id": "H3",
        "score": 0.47,
        "components": {
          "mechanism_fit": 0.5,
          "class_prior": 0.5,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.6,
          "safety_risk": 0.3,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.3
        },
        "graph_signals": {
          "support_weight": 1.65,
          "contradiction_weight": 1.55,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Azathioprine在调节免疫反应中起作用。"
          ],
          "safety_risk": [
            "潜在副作用未充分探讨。"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Azathioprine的确切机制与安全性尚不清楚。"
        ]
      },
      {
        "hypothesis_id": "H4",
        "score": 0.5,
        "components": {
          "mechanism_fit": 0.6,
          "class_prior": 0.5,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.3,
          "graph_bonus": 0.2,
          "conflict_penalty": 0.3
        },
        "graph_signals": {
          "support_weight": 1.6,
          "contradiction_weight": 1.55,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Budesonide通过抗炎细胞因子发挥作用。"
          ],
          "safety_risk": [
            "临床安全性数据强调潜在的副作用问题。"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Budesonide的长期效果与副作用尚需探讨。"
        ]
      },
      {
        "hypothesis_id": "H5",
        "score": 0.55,
        "components": {
          "mechanism_fit": 0.6,
          "class_prior": 0.5,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.25,
          "graph_bonus": 0.2,
          "conflict_penalty": 0.3
        },
        "graph_signals": {
          "support_weight": 1.6,
          "contradiction_weight": 1.55,
          "mechanistic_connectivity": true,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Ustekinumab针对TNF-alpha的抑制具有良好的临床支持。"
          ],
          "safety_risk": [
            "尽管有副作用风险，但总体安全性可接受。"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "需要更详细的关于副作用的信息。"
        ]
      },
      {
        "hypothesis_id": "H6",
        "score": 0.4,
        "components": {
          "mechanism_fit": 0.5,
          "class_prior": 0.4,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.3,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.3
        },
        "graph_signals": {
          "support_weight": 1.25,
          "contradiction_weight": 1.55,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Methotrexate在炎症管理中显示某种效果，但机制尚不明确。"
          ],
          "safety_risk": [
            "安全性问题仍需深入研究。"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Methotrexate的临床效果与副作用信息不足。"
        ]
      },
      {
        "hypothesis_id": "H7",
        "score": 0.43,
        "components": {
          "mechanism_fit": 0.4,
          "class_prior": 0.5,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.3,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.3
        },
        "graph_signals": {
          "support_weight": 1.4,
          "contradiction_weight": 1.55,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Certolizumab pegol显示对TNF-alpha的中等抑制活性。"
          ],
          "safety_risk": [
            "副作用表现需更有效的临床数据支持。"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Certolizumab pegol的长期效果及安全性尚不清楚。"
        ]
      },
      {
        "hypothesis_id": "H8",
        "score": 0.44,
        "components": {
          "mechanism_fit": 0.4,
          "class_prior": 0.5,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.3,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.3
        },
        "graph_signals": {
          "support_weight": 1.4,
          "contradiction_weight": 1.55,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Golimumab对TNF-alpha的抑制具备合理支持。"
          ],
          "safety_risk": [
            "需评估Golimumab的副作用在临床中的表现。"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Golimumab的用途在不同患者中的影响尚未充分讨论。"
        ]
      },
      {
        "hypothesis_id": "H9",
        "score": 0.39,
        "components": {
          "mechanism_fit": 0.3,
          "class_prior": 0.5,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.3,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.3
        },
        "graph_signals": {
          "support_weight": 1.2,
          "contradiction_weight": 1.55,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Vedolizumab作用于肠道局部炎症，但机制尚不明确。"
          ],
          "safety_risk": [
            "需考虑其副作用与实际效果之间的平衡。"
          ]
        },
        "confidence": "low",
        "uncertainties": [
          "Vedolizumab的临床效果及副作用仍需深入研究。"
        ]
      },
      {
        "hypothesis_id": "H10",
        "score": 0.32,
        "components": {
          "mechanism_fit": 0.2,
          "class_prior": 0.4,
          "pk_pd_feasibility": 0.4,
          "indication_plausibility": 0.3,
          "safety_risk": 0.3,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.3
        },
        "graph_signals": {
          "support_weight": 1.0,
          "contradiction_weight": 1.55,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Linaclotide的作用机制与炎症管理关系不大。"
          ],
          "safety_risk": [
            "Linaclotide的安全性数据有限，特别是在长时间使用时。"
          ]
        },
        "confidence": "low",
        "uncertainties": [
          "Linaclotide的效果与安全性需更多数据支持。"
        ]
      },
      {
        "hypothesis_id": "H11",
        "score": 0.34,
        "components": {
          "mechanism_fit": 0.2,
          "class_prior": 0.4,
          "pk_pd_feasibility": 0.4,
          "indication_plausibility": 0.3,
          "safety_risk": 0.3,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.3
        },
        "graph_signals": {
          "support_weight": 1.0,
          "contradiction_weight": 1.55,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Rifaximin的机制与肠上皮屏障疾病不直接相关。"
          ],
          "safety_risk": [
            "副作用与治疗效果尚需更好证据支持。"
          ]
        },
        "confidence": "low",
        "uncertainties": [
          "Rifaximin的效果及副作用数据需进一步评估。"
        ]
      },
      {
        "hypothesis_id": "H12",
        "score": 0.36,
        "components": {
          "mechanism_fit": 0.3,
          "class_prior": 0.4,
          "pk_pd_feasibility": 0.4,
          "indication_plausibility": 0.4,
          "safety_risk": 0.3,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.3
        },
        "graph_signals": {
          "support_weight": 1.0,
          "contradiction_weight": 1.55,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": []
        },
        "rationales": {
          "mechanism_fit": [
            "Eluxadoline在治疗相关病症上有一定作用，但机制需更明确。"
          ],
          "safety_risk": [
            "安全性关于副作用的确认不足。"
          ]
        },
        "confidence": "low",
        "uncertainties": [
          "Eluxadoline的疗效与安全性之间的折衷尚需更多数据支持。"
        ]
      }
    ],
    "ranking": [
      "H5",
      "H2",
      "H4",
      "H3",
      "H1",
      "H8",
      "H7",
      "H6",
      "H9",
      "H12",
      "H11",
      "H10"
    ],
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "drug_mesalamine",
          "type": "Drug",
          "label": "Mesalamine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_azathioprine",
          "type": "Drug",
          "label": "Azathioprine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_budesonide",
          "type": "Drug",
          "label": "Budesonide",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_certolizumab_pegol",
          "type": "Drug",
          "label": "Certolizumab pegol",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_golimumab",
          "type": "Drug",
          "label": "Golimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_vedolizumab",
          "type": "Drug",
          "label": "Vedolizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "disease_gastrointestinal_disorder",
          "type": "Disease",
          "label": "Gastrointestinal epithelial barrier disorders",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "target_TNF_alpha",
          "type": "Target",
          "label": "TNF-alpha",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "pathway_inflammatory_response",
          "type": "Pathway",
          "label": "Inflammatory Response Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "phenotype_mucosal_healing",
          "type": "Phenotype",
          "label": "Mucosal Healing",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "phenotype_inflammation_management",
          "type": "Phenotype",
          "label": "Inflammation Management",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ot_mesalamine",
          "type": "Target",
          "label": "Mesalamine Off-Target Effects",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_mesalamine",
          "type": "Pathway",
          "label": "Mesalamine Risk Pathway",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_mesalamine",
          "type": "Phenotype",
          "label": "Adverse Effects of Mesalamine",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_infliximab",
          "type": "Target",
          "label": "Infliximab Off-Target Effects",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_infliximab",
          "type": "Pathway",
          "label": "Infliximab Risk Pathway",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_infliximab",
          "type": "Phenotype",
          "label": "Adverse Effects of Infliximab",
          "attrs": {
            "agent": "Skeptic"
          }
        }
      ],
      "edges": [
        {
          "source": "drug_mesalamine",
          "target": "target_TNF_alpha",
          "relation": "inhibits",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "已知 Mesalamine 对 TNF-alpha 的抑制作用"
        },
        {
          "source": "target_TNF_alpha",
          "target": "pathway_inflammatory_response",
          "relation": "involved_in",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "TNF-alpha 在炎症反应通路中的核心作用"
        },
        {
          "source": "pathway_inflammatory_response",
          "target": "disease_gastrointestinal_disorder",
          "relation": "causes",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "炎症通路与胃肠上皮屏障障碍相关"
        },
        {
          "source": "drug_infliximab",
          "target": "target_TNF_alpha",
          "relation": "inhibits",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "Infliximab 直接靶向 TNF-alpha"
        },
        {
          "source": "drug_azathioprine",
          "target": "pathway_inflammatory_response",
          "relation": "modulates",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "Azathioprine 通过调节免疫通路改善炎症"
        },
        {
          "source": "drug_budesonide",
          "target": "pathway_inflammatory_response",
          "relation": "activates",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Budesonide 通过促进抗炎细胞因子发挥作用"
        },
        {
          "source": "drug_ustekinumab",
          "target": "target_TNF_alpha",
          "relation": "inhibits",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Ustekinumab 抑制 TNF-alpha 途径"
        },
        {
          "source": "drug_methotrexate",
          "target": "pathway_inflammatory_response",
          "relation": "inhibits",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Methotrexate 通过抑制细胞增殖改善炎症"
        },
        {
          "source": "drug_golimumab",
          "target": "target_TNF_alpha",
          "relation": "inhibits",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "Golimumab 对 TNF-alpha 的特异性抑制"
        },
        {
          "source": "drug_vedolizumab",
          "target": "pathway_inflammatory_response",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Vedolizumab 对肠道局部炎症有针对性作用"
        },
        {
          "source": "target_TNF_alpha",
          "target": "phenotype_mucosal_healing",
          "relation": "supports",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "抑制 TNF-alpha 可促进黏膜愈合"
        },
        {
          "source": "pathway_inflammatory_response",
          "target": "phenotype_inflammation_management",
          "relation": "supports",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "Inflammatory Response Pathway 相关于炎症管理"
        },
        {
          "source": "drug_azathioprine",
          "target": "phenotype_inflammation_management",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "Azathioprine 在炎症管理中的应用"
        },
        {
          "source": "drug_mesalamine",
          "target": "n_ot_mesalamine",
          "relation": "acts_on",
          "weight": 0.65,
          "agent": "Skeptic",
          "rationale": "Potential off-target effects may contribute to adverse outcomes."
        },
        {
          "source": "n_ot_mesalamine",
          "target": "n_rp_mesalamine",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "Risk pathway involvement suggests adverse consequences."
        },
        {
          "source": "n_rp_mesalamine",
          "target": "n_adv_mesalamine",
          "relation": "causes",
          "weight": 0.75,
          "agent": "Skeptic",
          "rationale": "May lead to significant adverse phenotypes."
        },
        {
          "source": "n_adv_mesalamine",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "If risks materialize, they could negate perceived benefits."
        },
        {
          "source": "drug_infliximab",
          "target": "n_ot_infliximab",
          "relation": "acts_on",
          "weight": 0.65,
          "agent": "Skeptic",
          "rationale": "Potential off-target effects may contribute to adverse outcomes."
        },
        {
          "source": "n_ot_infliximab",
          "target": "n_rp_infliximab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "Risk pathway involvement suggests adverse consequences."
        },
        {
          "source": "n_rp_infliximab",
          "target": "n_adv_infliximab",
          "relation": "causes",
          "weight": 0.75,
          "agent": "Skeptic",
          "rationale": "May lead to significant adverse phenotypes."
        },
        {
          "source": "n_adv_infliximab",
          "target": "H2",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "If risks materialize, they could negate perceived benefits."
        }
      ],
      "round_index": 4
    },
    "history": {
      "round": 4
    },
    "thresholds": {
      "stop_delta": 0.03,
      "saturation_ratio": 0.65,
      "weights": {
        "path_disjointness": 1.0
      }
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "final_recommendations": [
      {
        "hypothesis_id": "H5",
        "candidate": {
          "id": "drug_ustekinumab",
          "name": "Ustekinumab"
        },
        "score": 0.55,
        "graph_snapshot_ref": "GE_H5_round5",
        "key_assumptions": [
          "Ustekinumab maintains effective TNF-alpha suppression.",
          "The safety profile is manageable despite known risks."
        ],
        "caveats": [
          "More detailed assessments of side effects are necessary."
        ],
        "confidence": "medium"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "Drug→Target(TNF-alpha)→Pathway(inflammatory response)→Disease(gastrointestinal disorder)",
          "reason": "The pathway connecting Ustekinumab's action to its therapeutic effects appears robust."
        }
      ],
      "remaining_gaps": [
        "Adverse effect assessments for Ustekinumab should be further clarified."
      ]
    },
    "seed_retrospective": {
      "batches": [
        {
          "round": 1,
          "seeds": [
            "A",
            "B",
            "C",
            "D"
          ],
          "impact_summary": "Initial hypotheses established foundational links with TNF-alpha."
        },
        {
          "round": 2,
          "seeds": [
            "E",
            "F"
          ],
          "impact_summary": "Safety concerns persisted; need for deeper investigation into adverse effects."
        }
      ],
      "lessons": [
        "Continuously reassess the risk-benefit profile of drugs with known adverse effects.",
        "Establish pathways for new candidates that maintain therapeutic integrity while minimizing risks."
      ]
    },
    "prompt_patches": [
      {
        "role": "Proponent",
        "patch": "Detail supportive evidence for each drug’s mechanism of action in relation to their effectiveness."
      },
      {
        "role": "Skeptic",
        "patch": "Identify the critical minimum data points for adverse effects and treatment outcomes."
      },
      {
        "role": "Explorer",
        "patch": "Focus on generating candidates that target distinct mechanisms to avoid overlap with existing therapies."
      }
    ],
    "heuristics": [
      {
        "when": "Gastrointestinal disorders",
        "then": "Evaluate patient-reported outcomes regarding drug efficacy and side effects."
      },
      {
        "when": "Drug candidates show safety concerns",
        "then": "Investigate alternative drugs with better safety profiles."
      }
    ]
  }
}